Varun Saxena from fiercemedicaldevices.com wrote an interesting article on the proposed plan of Expedited Access PMA (EAP). The FDA talked about how EAP is not a new path to market but a collaborative approach to facilitate product development under existing FDA guidelines. It is targeted for a very specific type of high-risk medical devices and allows the company to interact early and on a regular basis with FDA. Quoted in the article was CDRH Director Jeffrey Shuren, “We are excited to offer a proposed program for expedited access for certain high-risk medical devices.” To read the full article click here.
Obstacles Facing Biosimilars
Still in its infancy in the U.S., the industry faces some growing pains.
Life Science Accelerated
Our experts are dedicated to expediting life science product development regulatory pathways.